Estimated glomerular filtration rate and systolic time intervals in risk stratification for increased left ventricular mass index and left ventricular hypertrophy

Medicine (United States)

Volumn 95, Issue 10, 2016, Pages

  Lee, Wen Hsien ^a,b,c   Hsu, Po Chao ^b   Chu, Chun Yuan ^b   Chen, Szu Chia ^a,b,c   Lee, Hung Hao ^b   Lee, Meng Kuang ^b,c   Lee, Chee Siong ^b   Yen, Hsueh Wei ^b   Lin, Tsung Hsien ^b   Voon, Wen Chol ^b   Lai, Wen Ter ^b   Sheu, Sheng Hsiung ^b   Su, Ho Ming ^b,c  

^a Graduate Institute of Clinical Medicine   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CEREBROVASCULAR DISEASE; DIABETES MELLITUS; FEMALE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART PREEJECTION PERIOD; HEART RATE; HEART VENTRICLE EJECTION TIME; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; SMOKING; SYSTOLIC BLOOD PRESSURE; SYSTOLIC TIME INTERVAL; CHRONIC KIDNEY FAILURE; HEART VENTRICLE; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; SYSTOLE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; FEMALE; GLOMERULAR FILTRATION RATE; HEART VENTRICLES; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; SYSTOLE;

EID: 84962606676     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000002917     Document Type: Article

References (37)

1. Cuspidi C, Meani S, Valerio C, et al. Left ventricular hypertrophy and cardiovascular risk stratification: impact and cost-effectiveness of echocardiography in recently diagnosed essential hypertensives. J Hypertens. 2006;24:1671-1677.
2. Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation. 2000;102:470-479.
3. Chahal NS, Lim TK, Jain P, et al. New insights into the relationship of left ventricular geometry and left ventricular mass with cardiac function: A population study of hypertensive subjects. Eur Heart J. 2010;31:588-594.
4. Myerson SG, Montgomery HE, World MJ, et al. Left ventricular mass: reliability of m-mode and 2-dimensional echocardiographic formulas. Hypertension. 2002;40:673-678.
5. Paoletti E, Bellino D, Cassottana P, et al. Left ventricular hypertrophy in nondiabetic predialysis CKD. Am J Kidney Dis. 2005;46:320-327.
6. Tucker B, Fabbian F, Giles M, et al. Left ventricular hypertrophy and ambulatory blood pressure monitoring in chronic renal failure. Nephrol Dial Transplant. 1997;12:724-728.
7. Paoletti E. Left ventricular hypertrophy and progression of chronic kidney disease. J Nephrol. 2012;25:847-850.
8. Nardi E, Palermo A, Mule G, et al. Left ventricular hypertrophy and geometry in hypertensive patients with chronic kidney disease. J Hypertens. 2009;27:633-641.
9. Elsayed EF, Tighiouart H, Griffith J, et al. Cardiovascular disease and subsequent kidney disease. Arch Intern Med. 2007;167:1130-1136.
10. Tsuruya K, Eriguchi M. Cardiorenal syndrome in chronic kidney disease. Curr Opin Nephrol Hypertens. 2015;24:154-162.
11. Van de Werf F, Piessens J, Kesteloot H, et al. A comparison of systolic time intervals derived from the central aortic pressure and from the external carotid pulse tracing. Circulation. 1975;51:310-316.
12. Su HM, Lin TH, Hsu PC, et al. A comparison between brachial and echocardiographic systolic time intervals. PLoS One. 2013;8:e55840.
13. Polak JF, Alessi-Chinetti JM, Estes JM, et al. Left ventricular ejection time derived from the common carotid artery Doppler waveform: association with left ventricular ejection fraction and prediction of heart failure. J Ultrasound Med. 2015;34:1237-1242.
14. Gillebert TC, Van de Veire N, De Buyzere ML, et al. Time intervals and global cardiac function. Use and limitations. Eur Heart J. 2004;25:2185-2186.
15. Chen SC, Chang JM, Liu WC, et al. Significant correlation between ratio of brachial pre-ejection period to ejection time and left ventricular ejection fraction and mass index in patients with chronic kidney disease. Nephrol Dial Transplant. 2011;26:1895-1902.
16. Chen SC, Chang JM, Tsai JC, et al. A systolic parameter defined as the ratio of brachial pre-ejection period to brachial ejection time predicts cardiovascular events in patients with chronic kidney disease. Circ J. 2010;74:2206-2210.
17. Chen SC, Chang JM, Tsai JC, et al. A new systolic parameter defined as the ratio of brachial pre-ejection period to brachial ejection time predicts overall and cardiovascular mortality in hemodialysis patients. Hypertens Res. 2010;33:492-498.
18. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440-1463.
19. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450-458.
20. Su HM, Lin TH, Lee CS, et al. Myocardial performance index derived from brachial-ankle pulse wave velocity: A novel and feasible parameter in evaluation of cardiac performance. Am J Hypertens. 2009;22:871-876.
21. Vickery S, Stevens PE, Dalton RN, et al. Does the id-ms traceable MDRD equation work and is it suitable for use with compensated jaffe and enzymatic creatinine assays? Nephrol Dial Transplant. 2006;21:2439-2445.
22. Boudoulas H, Mantzouratos D, Sohn YH, et al. Left ventricular mass and systolic performance in chronic systemic hypertension. Am J Cardiol. 1986;57:232-237.
23. Su HM, Lin TH, Hsu PC, et al. Impact of systolic time intervals on the relationship between arterial stiffness and left ventricular hypertrophy. Atherosclerosis. 2012;223:171-176.
24. Bock JS, Gottlieb SS. Cardiorenal syndrome: new perspectives. Circulation. 2010;121:2592-2600.
25. Bruch C, Rothenburger M, Gotzmann M, et al. Chronic kidney disease in patients with chronic heart failure-impact on intracardiac conduction, diastolic function and prognosis. Int J Cardiol. 2007;118:375-380.
26. Stewart GA, Gansevoort RT, Mark PB, et al. Electrocardiographic abnormalities and uremic cardiomyopathy. Kidney Int. 2005;67:217-226.
27. Selvetella G, Lembo G. Mechanisms of cardiac hypertrophy. Heart Fail Clin. 2005;1:263-273.
28. Nadruz W. Myocardial remodeling in hypertension. J Hum Hypertens. 2015;29:1-6.
29. Lanni F, Santulli G, Izzo R, et al. The Pl (A1/A2) polymorphism of glycoprotein IIIa and cerebrovascular events in hypertension: increased risk of ischemic stroke in high-risk patients. J Hypertens. 2007;25:551-556.
30. Galasso G, Santulli G, Piscione F, et al. The GPIIIa pla2 polymorphism is associated with an increased risk of cardiovascular adverse events. BMC Cardiovasc Disord. 2010;10:41.
31. Santulli G, Trimarco B, Iaccarino G. G-protein-coupled receptor kinase 2 and hypertension: molecular insights and pathophysiological mechanisms. High Blood Press Cardiovasc Prev. 2013;20:5-12.
32. Ferguson SS, Feldman RD. Beta-adrenoceptors as molecular targets in the treatment of hypertension. Can J Cardiol. 2014;30:S3-S8.
33. Kim J, Ahn S, Ren XR, et al. Functional antagonism of different G protein-coupled receptor kinases for beta-arrestin-mediated angiotensin II receptor signaling. Proc Natl Acad Sci. 2005;102:1442-1447.
34. Sorriento D, Santulli G, Franco A, et al. Integrating GRK2 and NFkappaB in the pathophysiology of cardiac hypertrophy. J Cardiovasc Transl Res. 2015;8:493-502.
35. Cipolletta E, Rusciano MR, Maione AS, et al. Targeting the CaMKII/ERK interaction in the heart prevents cardiac hypertrophy. PLoS One. 2015;10:e0130477.
36. Sorriento D, Santulli G, Fusco A, et al. Intracardiac injection of adGRK5-NT reduces left ventricular hypertrophy by inhibiting NFkappaB-dependent hypertrophic gene expression. Hypertension. 2010;56:696-704.
37. Santulli G, Cipolletta E, Sorriento D, et al. CaMK4 gene deletion induces hypertension. J Am Heart Assoc. 2012;1:e001081.